Two long-acting antiretrovirals, lenacapavir (Sunlenca) and cabotegravir (Vocabria), may pair well with broadly neutralising antibodies for HIV treatment, according to two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI 2024).
Monoclonal antibodies are manufactured proteins that work like natural antibodies made by the immune system. People living with HIV normally produce HIV-specific antibodies, but these mostly target parts of the virus that are hidden or highly variable. However, a small proportion of people make broadly neutralising antibodies (bnAbs) that target conserved parts of the virus that don’t change much. These specialised antibodies are being explored for HIV prevention, treatment and cure research. As with antiretroviral drugs, though, the virus can develop resistance to bnAbs, so they are best used in combination therapy.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.